Skip to content

Change in Other Assets at other companies

Pfizer logo
PfizerPFE
-$322.25M+61.9%
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
-$7.84M-30.8%
Immunome logo
ImmunomeIMNM
$5.1M+199%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$3M
Cogent Biosciences, Inc. logo
Cogent Biosciences, Inc.COGT
$1.84M+184%
Incyte logo
IncyteINCY
-$9.19M-115%

Other financials

Income statement

See full
Revenue-
Gross profit-
Operating income-$9.3M-52.6%
Net income-$8.4M-44.6%
EPS (diluted)-$0.05+28.6%

Balance sheet

See full
Cash & equivalents$107.1M+277%
Total debt$871.0K+0.1%
Total equity$107.4M+287%
Total assets$114.2M+227%

Cash flow

See full
Operating cash flow-$8.8M+2.5%

Valuation

See full
Market cap$1.78B+674%
Enterprise value$1.68B+826%

Profitability

See full
Gross margin90%-7.4pp
Operating margin-4,195%-4,591pp
Net margin-4,130.1%-4,444pp
FCF margin-300.5%

Returns & leverage

See full
Return on equity-43.6%-17.9pp
Debt / equity0.0×
Current ratio17.2×+12.6×

Where this comes from

Reported directly by SELLAS Life Sciences Group, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets.

The official record: SELLAS Life Sciences Group, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about SELLAS Life Sciences Group, Inc.'s change in other assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is SELLAS Life Sciences Group, Inc.'s change in other assets?
SELLAS Life Sciences Group, Inc. (SLS) reported change in other assets of $652K in Q1 2026.
How has SELLAS Life Sciences Group, Inc.'s change in other assets changed year-over-year?
SELLAS Life Sciences Group, Inc.'s change in other assets decreased by 42.4% year-over-year, from $1.13M to $652K.
What does change in other assets mean?
Change in miscellaneous assets affecting operating cash flow.